Barclays’s Faeth Therapeutics FTH Stock Holding History

Barclays’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-128	Closed	-$1.01K	–	5520
2025 Q1	$1.01K	Buy	+128	New	+$1.22K	﹤0.01%	5049
2022 Q3	–	Sell	-10	Closed	–	–	5110
2022 Q2	$0	Sell	10 -160	-94%	-$6K	﹤0.01%	5236
2022 Q1	$8K	Buy	+170	New	+$13.5K	﹤0.01%	4639

Other funds holding FTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Barclays's FTH Position: Q2 2025 in Review

Barclays sold out of Faeth Therapeutics (FTH) in Q2 2025, closing a stake of 128 shares — an estimated $1.01K sold.

Barclays first reported a position in FTH in Q1 2022 and held it in 3 quarters. The position peaked at $8K in Q1 2022. 10 funds tracked by Wall St. Rank hold FTH as of Q2 2025.

Barclays reported no remaining Faeth Therapeutics position as of Q2 2025 after selling out during the quarter.
Barclays sold 128 Faeth Therapeutics shares in Q2 2025, an estimated $1.01K.
Barclays first reported a position in Faeth Therapeutics in Q1 2022 and held it in 3 quarters.
Barclays's Faeth Therapeutics position peaked at $8K in Q1 2022.
10 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.